Gabapentin Solution
Product Images NDC 60687-919

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 60687-919). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

300 mg (6 mL Gabapentin Oral Solution Cup Lid.jpg)

Label for Gabapentin Oral Solution 300 mg per 6 mL, a human prescription drug by American Health Packaging. The label indicates this solution delivers 6 mL per dose and includes storage instructions to keep refrigerated between 2°C to 8°C (36°F to 46°F) and guidance to see the full prescribing information.*

FDA Label Image

Clcr (Gaba Os 1)

An illustration showing the formula for calculating creatinine clearance (CLCr) based on patient age in years, weight in kilograms, serum creatinine in mg/dL, and an adjustment factor of 0.85 for female patients.*

FDA Label Image

Structure (Gaba Os 2)

Chemical structure diagram of gabapentin showing a cyclohexane ring bonded to an amino methyl group and a carboxymethyl group.*

FDA Label Image

Figure 1 (Gaba Os 3)

A line graph depicting mean pain scores over an 8-week period comparing placebo and Gabapentin 3600 mg/day. The x-axis shows weeks from baseline to week 8, and the y-axis shows mean pain scores from 0 to 10. The graph is divided into a 4-week dose titration period and a 4-week fixed dose period.*

FDA Label Image

Figure 2 (Gaba Os 4)

A line graph depicting mean pain scores over 7 weeks for three groups: Placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks, starting from baseline through week 7, and the y-axis shows mean pain scores. Two study periods are indicated: a 3-week dose titration period and a 4-week fixed dose period. Gabapentin groups show a decrease in mean pain score compared to placebo over time.*

FDA Label Image

Figure 3 (Gaba Os 5)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) with Gabapentin (GBP) dosed at 3600 mg in Study 1, and GBP dosed at 1800 mg and 2400 mg in Study 2. The chart presents percentage responders with values approximately 12% and 29% in Study 1, and 14%, 32%, and 34% in Study 2. Statistical significance is indicated for the GBP groups.*

FDA Label Image

Figure 4 (Gaba Os 6)

A scatterplot chart showing percentage difference on the vertical axis versus daily dose in milligrams on the horizontal axis for Gabapentin. The chart compares three studies labeled 'a', 'b', and 'c', with data points at 600 mg, 900 mg, 1200 mg, and 1800 mg doses indicating variance among the studies.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.